Chimpanzee adenovirus- and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults.
Respiratory syncytial virus (RSV) causes respiratory infection in annual epidemics, with infants and the elderly at particular risk of developing severe disease and death. However, despite its importance, no vaccine exists. The chimpanzee adenovirus, PanAd3-RSV, and modified vaccinia virus Ankara, M...
Main Authors: | Green, C, Scarselli, E, Sande, C, Thompson, A, de Lara, C, Taylor, K, Haworth, K, Del Sorbo, M, Angus, B, Siani, L, Di Marco, S, Traboni, C, Folgori, A, Colloca, S, Capone, S, Vitelli, A, Cortese, R, Klenerman, P, Nicosia, A, Pollard, A |
---|---|
Format: | Journal article |
Language: | English |
Published: |
American Association for the Advancement of Science
2015
|
Similar Items
-
Novel genetically-modified chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine safely boosts humoral and cellular immunity in healthy older adults
by: Green, C, et al.
Published: (2019) -
Safety and immunogenicity of novel respiratory syncytial virus (RSV) vaccines based on the RSV viral proteins F, N and M2-1 encoded by simian adenovirus (PanAd3-RSV) and MVA (MVA-RSV); protocol for an open-label, dose-escalation, single-centre, phase 1 clinical trial in healthy adults.
by: Green, C, et al.
Published: (2015) -
Chimpanzee adenoviral vectors as vaccines – challenges to move the technology into the fast lane
by: Alessandra Vitelli, et al.
Published: (2017-12-01) -
Transcriptomic response and immunological responses to chimpanzee adenovirus- and MVA viral-vectored vaccines for RSV in healthy adults
by: Green, C, et al.
Published: (2023) -
Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation
by: Ewer, K, et al.
Published: (2013)